With Geron Deal Done, AngioChem Turns To Its Own Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
You may also be interested in...
In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.
Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets
In terms of oncology alliances, 2009 is shaping up as slower than the previous three years, but the number of significantly priced deals has not decreased greatly